United States : ALITAIR resin-formulated cough product gets NOA.
The patent includes the potential of the resin-formulated drug in decreasing or eliminating the choking hazard, which is connected with conventional liquid formulations of benzonatate.
Alitair president and CEO William Howard said: "Our oral solid ion exchange resin formulation has been shown to reduce or eliminate the choking hazard.
"Our proprietary technology allows us to bind benzonatate to a resin particle, which represents a completely novel formulation approach and resolves this significant safety issue.
Howard added: "This Notice of Allowance marks an important milestone in our benzonatate product development strategy and may be the key to benzonatate becoming a successful Rx-to-OTC switch candidate."
2012 Al Bawaba (Albawaba.com)
Provided by Syndigate.info an Albawaba.com company
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 30, 2012|
|Previous Article:||United States : WIKODA launches new PV TRACKER product.|
|Next Article:||United States : MITSUBISHI ELECTRIC enters into agreement with HDA TRUCK PRIDE.|